Literature DB >> 10704203

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.

L Runkel1, C deDios, M Karpusas, M Betzenhauser, C Muldowney, M Zafari, C D Benjamin, S Miller, P S Hochman, A Whitty.   

Abstract

A systematic mutational analysis of human interferon-beta-1a (IFN-beta) was performed to identify regions on the surface of the molecule that are important for receptor binding and for functional activity. The crystal structure of IFN-beta-1a was used to design a panel of 15 mutant proteins, in each of which a contiguous group of 2-8 surface residues was mutated, in most instances to alanine. The mutants were analyzed for activity in vitro in antiviral and in antiproliferation assays, and for their ability to bind to the type I IFN (ifnar1/ifnar2) receptor on Daudi cells and to a soluble ifnar2 fusion protein (ifnar2-Fc). Abolition of binding to ifnar2-Fc for mutants A2, AB1, AB2, and E established that the ifnar2 binding site on IFN-beta comprises parts of the A helix, the AB loop, and the E helix. Mutations in these areas, which together define a contiguous patch of the IFN-beta surface, also resulted in reduced affinity for binding to the receptor on cells and in reductions in activity of 5-50-fold in functional assays. A second receptor interaction site, concluded to be the ifnar1 binding site, was identified on the opposite face of the molecule. Mutations in this region, which encompasses parts of the B, C, and D helices and the DE loop, resulted in disparate effects on receptor binding and on functional activity. Analysis of antiproliferation activity as a function of the level of receptor occupancy allowed mutational effects on receptor activation to be distinguished from effects on receptor binding. The results suggest that the binding energy from interaction of IFN-beta with ifnar2 serves mainly to stabilize the bound IFN/receptor complex, whereas the binding energy generated by interaction of certain regions of IFN-beta with ifnar1 is not fully expressed in the observed affinity of binding but instead serves to selectively stabilize activated states of the receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704203     DOI: 10.1021/bi991631c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Quantitative analysis of receptor tyrosine kinase-effector coupling at functionally relevant stimulus levels.

Authors:  Simin Li; Devayani Bhave; Jennifer M Chow; Thomas V Riera; Sandra Schlee; Simone Rauch; Mariya Atanasova; Richard L Cate; Adrian Whitty
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

Review 2.  PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.

Authors:  Bernd C Kieseier; Peter A Calabresi
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

3.  Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2011-05-05       Impact factor: 4.200

4.  Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-05-25       Impact factor: 4.200

5.  Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Steven A Berkowitz; Damian Houde
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-29       Impact factor: 3.109

Review 6.  Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.

Authors:  Jacob Piehler; Christoph Thomas; K Christopher Garcia; Gideon Schreiber
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

7.  Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

Authors:  Diego A Jaitin; Laila C Roisman; Eva Jaks; Martynas Gavutis; Jacob Piehler; Jose Van der Heyden; Gilles Uze; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

8.  NMR mapping of the IFNAR1-EC binding site on IFNalpha2 reveals allosteric changes in the IFNAR2-EC binding site.

Authors:  Sabine Ruth Akabayov; Zohar Biron; Peter Lamken; Jacob Piehler; Jacob Anglister
Journal:  Biochemistry       Date:  2010-02-02       Impact factor: 3.162

9.  The differential antiviral activities of chicken interferon α (ChIFN-α) and ChIFN-β are related to distinct interferon-stimulated gene expression.

Authors:  Hongren Qu; Limin Yang; Shanshan Meng; Lei Xu; Yuhai Bi; Xiaojuan Jia; Jing Li; Lei Sun; Wenjun Liu
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Optimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects.

Authors:  Normand E Allaire; Steven E Bushnell; Jadwiga Bienkowska; Graham Brock; John Carulli
Journal:  BMC Res Notes       Date:  2013-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.